Intrommune Logo Only - 250k.jpg
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
November 07, 2019 10:00 ET | Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
September 16, 2019 14:25 ET | Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
September 13, 2019 09:05 ET | Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Intrommune Logo Only - 250k.jpg
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
September 05, 2019 15:20 ET | Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
August 21, 2019 14:41 ET | Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
May 17, 2019 13:25 ET | Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET | Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET | Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
September 06, 2018 07:11 ET | Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 15, 2018 12:00 ET | Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...